---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-218004"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:54:08.890768+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Verrica Q2 net loss $10.2M; plans VP-102 NDA resubmission in Q1 2023

## Summary
- Q2 2022 net loss $10.2M ($0.37 GAAP EPS); non-GAAP net loss $8.8M ($0.32/share).
- License revenue $0.2M from Torii; R&D $4.2M, G&A $5.2M.
- Held Type A FDA meeting; began working with Piramal for VP-102 bulk solution.
- Raised $28.5M gross in July 2022 public offering at $2.10/share.
- Cash, equivalents, marketable securities, restricted cash $54.4M as of June 30, 2022.

## SEC filing metadata
- accession: 0001193125-22-218004
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312522218004/0001193125-22-218004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312522218004/d358754d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-218004
- JSON: https://secwatch.observer/filing/0001193125-22-218004.json
- Plain text: https://secwatch.observer/filing/0001193125-22-218004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.